Abstract | BACKGROUND: METHODS: This was a prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with surgery and radiation-refractory recurrent World Health Organization (WHO) grades II-III meningioma. An exploratory cohort enrolled patients with WHO grade I meningioma, hemangiopericytoma, or hemangioblastoma. Sunitinib was administered at 50 mg/d for days 1-28 of every 42-day cycle. The primary endpoint was the rate of 6-month progression-free survival (PFS6), with secondary endpoints of radiographic response rate, safety, PFS, and overall survival. Exploratory objectives include analysis of tumoral molecular markers and MR perfusion imaging. RESULTS: Thirty-six patients with high-grade meningioma (30 atypical and 6 anaplastic) were enrolled. Patients were heavily pretreated (median number of 5 recurrences, range 2-10). PFS6 rate was 42%, meeting the primary endpoint. Median PFS was 5.2 months (95% CI: 2.8-8.3 mo), and median overall survival was 24.6 months (95% CI: 16.5-38.4 mo). Thirteen patients enrolled in the exploratory cohort. Overall toxicity included 1 grade 5 intratumoral hemorrhage, 2 grade 3 and 1 grade 4 CNS/intratumoral hemorrhages, 1 grade 3 and 1 grade 4 thrombotic microangiopathy, and 1 grade 3 gastrointestinal perforation. Expression of VEGFR2 predicted PFS of a median of 1.4 months in VEGFR2-negative patients versus 6.4 months in VEGFR2-positive patients (P = .005). CONCLUSION:
Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.
|
Authors | Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic, Andrew Norden, Jan Drappatz, Eudocia Quant Lee, Benjamin Purow, Scott R Plotkin, Tracy Batchelor, Lauren E Abrey, Antonio Omuro |
Journal | Neuro-oncology
(Neuro Oncol)
Vol. 17
Issue 1
Pg. 116-21
(Jan 2015)
ISSN: 1523-5866 [Electronic] England |
PMID | 25100872
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Antineoplastic Agents
- Indoles
- Pyrroles
- Sunitinib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Cohort Studies
- Disease-Free Survival
- Female
- Humans
- Indoles
(adverse effects, therapeutic use)
- Kaplan-Meier Estimate
- Male
- Meningeal Neoplasms
(drug therapy, mortality)
- Meningioma
(drug therapy, mortality)
- Middle Aged
- Pyrroles
(adverse effects, therapeutic use)
- Sunitinib
- Treatment Outcome
|